Why Genelux Corporation’s (GNLX) Stock Is Up 5.34%
As of Thursday, September 17, Genelux Corporation’s GNLX share price has surged by 5.34%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Commentary & Analysis
Why Genelux Corporation’s (GNLX) Stock Is Up 7.74%
As of Thursday, September 10, Genelux Corporation’s GNLX share price has surged by 7.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Genelux Corporation’s (GNLX) Stock Is Up 5.49%
As of Thursday, August 27, Genelux Corporation’s GNLX share price has surged by 5.49%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genelux Corporation’s (GNLX) Stock Is Up 6.35%
As of Wednesday, August 19, Genelux Corporation’s GNLX share price has surged by 6.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genelux Corporation’s (GNLX) Stock Is Up 5.38%
As of Thursday, August 06, Genelux Corporation’s GNLX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | GNLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $112.9 | $257.1 | 23% |
|
| Shares Out (Mil) | 45.0 | 54.0 | 45% |
|
| Institutional Ownership | 70.3% | 93.2% | 43% |
|
| Float (Mil) | 36.4 | 41.3 | 40% |
|
| Beta | 0.59 | 0.95 | 35% |
|
| Avg Daily Volume (000s) | 165 | 728 | 40% |
|
| Price Change (52-week) |
(40.7%) | 50.6% | 22% |
|
| Growth | GNLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (18.7%) | (10.1%) | 21% |
|
| EPS (5yr) | 11.9% | 15.7% | 51 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (15.7%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.198) | ($0.815) | ($0.752) | |
| Month Ago EPS | ($0.194) | ($0.806) | ($0.742) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.203) | ($0.815) | ($0.762) | |
| Year/Year Chg | (6.2%) | (5.8%) | (72.8%) | |
| Financials | GNLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($36) | ($44) | 19% |
|
| EPS (TTM) | ($0.862) | ($1.600) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $2 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $107 | $173 | 22% |
|
| Valuation | GNLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.00 | 2.52 | 86% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GNLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.2% | 96% |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (121.8%) | (47.7%) | 4% |
|
| ROE | (177.9%) | (54.9%) | 5% |
|
| Liabilities to Assets | 38.5% | 29.0% | 29% |
|
| F-Score | 1 | 3 | 1% |
|
Genelux Corporation did not pass any screens on 9/30/2026.
